The latest update is out from Innate Pharma SA ( (FR:IPH) ).
Innate Pharma announced its participation in the 2025 Leerink Partners Global Healthcare Conference, scheduled for March 10-12 in Miami, Florida. Members of the executive team will present and engage in one-on-one meetings, with a fireside chat on March 11. This participation underscores Innate Pharma’s active engagement in the healthcare industry and provides an opportunity to showcase its innovative cancer therapies to a global audience, potentially impacting its market positioning and stakeholder relations.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes its proprietary ANKET® platform for multi-specific NK Cell Engagers, along with Antibody Drug Conjugates and monoclonal antibodies, to target various tumor types. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a presence in the US.
Average Trading Volume: 875
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $195.8M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.